1. Introduction {#sec1-molecules-21-00678}
===============

*Ganoderma lucidum* (Leyss. ex Fr.) Karstis is one of the most highly used medicinal fungi in the world. Its fruiting body, called Lingzhi or Reishi, has been widely used in traditional Chinese medicine (TCM) as a dietary supplement and medicinal herb in China and other eastern countries for health promotion. Modern medical research has indicated that *G. lucidum* had comprehensive biological activities, such as anti-cancer, anti-inflammatory, immune-modulating, anti-oxidant, anti-microbial, anti-HIV-1, and so on, between which the most attractive is anti-cancer activity \[[@B1-molecules-21-00678],[@B2-molecules-21-00678],[@B3-molecules-21-00678],[@B4-molecules-21-00678],[@B5-molecules-21-00678],[@B6-molecules-21-00678],[@B7-molecules-21-00678],[@B8-molecules-21-00678],[@B9-molecules-21-00678]\].

To date, over 400 compounds were isolated and identified from *G. lucidum*. Wherein, more than 150 compounds belonged to GTs which were regarded as the main medicinal components, such as ganoderic acid A (GA-A), GA-C~2~, GA-D, GA-DM, lactone, ganoderiol F, ganodermanotriol, and so on \[[@B10-molecules-21-00678],[@B11-molecules-21-00678],[@B12-molecules-21-00678],[@B13-molecules-21-00678],[@B14-molecules-21-00678],[@B15-molecules-21-00678]\]. Accumulating evidence has shown that GTs can inhibit the proliferation of hepatoma cells and HeLa cells, as well as human colon cancer cells HT-29 \[[@B16-molecules-21-00678],[@B17-molecules-21-00678],[@B18-molecules-21-00678]\]. However, the structures and pharmacological activities of some GTs from *G. lucidum* are still unknown.

Virtual screening is an effective method to predict the biological activity of compounds \[[@B19-molecules-21-00678]\]. Pharmacophore-based activity profiling is a high-performance virtual screening method \[[@B20-molecules-21-00678]\], which can discover potential therapeutic targets of compounds. Generally, TCM compounds with diversified structures have multi-targets effect \[[@B21-molecules-21-00678],[@B22-molecules-21-00678]\]. Therefore, holistic analysis of the relationship and biological process of TCM therapeutic targets is beneficial to reveal the pharmacological activities of TCM compounds. Ingredient-target interaction network and protein interaction network (PIN) are two main types of bioinformatics methods to research the multi-target pharmacological effect of compounds. Ingredient-target interaction network is commonly constructed by experimental or predicted information of ingredient-target interactome, which can reflect the therapeutic targets of compounds directly. PIN is constructed by protein-protein interactions (PPIs), which refer to the major link of the biological process of therapeutic targets \[[@B23-molecules-21-00678]\]. Meanwhile, module-based network analysis of PIN is able to explore the biological effect of TCM therapeutic targets and initially identify the pharmacological activities of a single or class of TCM compound \[[@B24-molecules-21-00678],[@B25-molecules-21-00678]\].

Several *in silico* anti-cancer pharmacological prediction and profiling of GTs had been attempted. According to the docking studies of anti-cancer targets IKK1 and IKK2, Balraj \[[@B26-molecules-21-00678]\] discovered GA-A and GA-H might have the potential anti-cancer activities for NF-κB signaling pathway. Anti-cancer mechanism of GA-D was also discussed by QingXi \[[@B27-molecules-21-00678]\]. GA-D was docked into anti-cancer target-related proteins identified by cell experiments, and hit proteins were considered to interact with GA-D. PINs were then constructed to discuss the anti-cancer mechanism of GA-D and the contribution of these anti-cancer target-related proteins. Generally, existing research mainly focused on pharmacological prediction of single GT compound. However, the activity prediction of a class of GTs with similar structural framework and functional group should also be concerned.

In order to search for more active GTs from *G. lucidum*, studies on chemical constituents of *G. lucidum* and their biological activity prediction were carried out deeply and systematically. Solvent extraction and silica gel column chromatography were utilized to isolate the novel active constituents from the fruiting bodies of *G. lucidum*, including GTs, sterides and cerebrosides. Then, reverse target identification of novel isolated GTs was implemented by pharmacophore database and hit targets were used to construct ingredient-target network. Thereafter, high frequency targets from ingredient-target network were selected and their target-related proteins were utilized to construct PIN. According to the results of module analysis of PIN, anti-cancer modules were recognized and pharmacological activity of GTs was explained by gene ontology (GO) enrichment analysis.

2. Results and Discussion {#sec2-molecules-21-00678}
=========================

2.1. Identification of the Compounds {#sec2dot1-molecules-21-00678}
------------------------------------

The structures of the isolated compounds were elucidated from the data obtained from ^1^H- and ^13^C-NMR spectra. 3β,7β,15β-trihydroxy-11,23-dioxo-lanost-8,16-dien-26-oic acid methyl ester (**1**) \[[@B28-molecules-21-00678]\], 3β,7β,15β-trihydroxy-11,23-dioxo-lanost-8,16-dien-26-oic acid (**2**) \[[@B28-molecules-21-00678]\], 3β,7β,15α,28-tetrahydroxy-11,23-dioxo-lanost-8,16-dien-26-oic acid (**3**) \[[@B29-molecules-21-00678]\], ganotropic acid (**4**) \[[@B29-molecules-21-00678]\], 26-nor-11,23-dioxo-5α-lanost-8-en-3β,7β,15α,25-tetrol (**5**) \[[@B30-molecules-21-00678]\], (3β,7α)-3,7-dihydroxylanosta-8,24- dien-11-one (**6**) \[[@B31-molecules-21-00678]\] were first reported from the species of *G. lucidum*. Meanwhile, (4*E*,8*E*)-*N*-[d]{.smallcaps}-2′-hydroxypalmitoyl-l-*O*-β-[d]{.smallcaps}-glucopyranosyl-9-methyl-4,8-spingodienine (**7**) \[[@B32-molecules-21-00678]\] and stigmasta-7,22-dien-3β,5α,6α-triol (**8**) \[[@B33-molecules-21-00678]\] were first reported from the genus *Ganodema*, together with 4,4,14α-trimethyl-3-oxo-5α-pregna-7,9(11)-dien-20*S*-carboxylate (**9**), lucidenic acid C (**10**), lucidone F (**11**), lucidone D (**12**), 7-oxo-ganoderic acid Z (**13**), ganosineniol A (**14**), ganoderic acid XL~1~ (**15**), ganoderic acid C~2~ (**16**), methyl ganoderate C (**17**), ganolucidic acid γ~a~ (**18**), methyl ganoderate C~2~ (**19**), lucidenic lactone (**20**), ganodericacid C (**21**), ganodermacetal (**22**) and ergosterol (**23**), and ergosta-7,22-dien-3-one (**24**).

Compound **1** was obtained as a yellow oily solid, yielded a positive reaction to 10% H~2~SO~4~--EtOH reagent. ^1^H-NMR (CD~3~OD, 500 MHz) δ: 3.57 (3H, s, O-Me), 2.91 (1H, dd, *J* = 8.4, 17.8 Hz, H-3), 4.96 (1H, dd, *J* = 7.2, 9.9 Hz, H-7), 5.49 (1H, s, H-15), 5.44 (1H, s, H-16), 2.78 (1H, m, H-1), 1.61 (2H, m, H-2), 0.95 (1H, m, H-5), 1.96 (1H, dd, *J* = 7.6, 17.6 Hz, H-6), 3.12 (1H, d, *J* = 15.0 Hz, H-12), 3.02 (1H, d, *J* = 15.0 Hz, H-12), 2.50 (1H, m, H-20), 2.54 (1H, dd, *J* = 6.8,16.6 Hz, H-22), 2.40 (1H, m, H-24), 2.73 (1H, m, H-25), 1.25 (3H, s, H-18), 1.22 (3H, s, H-19), 1.02 (3H, d, *J* = 6.4 Hz, H-21), 1.11 (3H, d, *J* = 7.1 Hz, H-27), 1.03 (3H, s, H-28), 1.01 (3H, s, H-29), 1.02 (3H, s, H-30); ^13^C-NMR (CD~3~OD, 125 MHz) δ: 34.77 (C-1), 28.65 (C-2), 77.03 (C-3), 39.24 (C-4), 49.52 (C-5), 28.59 (C-6), 69.32 (C-7), 161.39 (C-8), 141.47 (C-9), 39.20 (C-10), 199.79 (C-11), 46.65 (C-12), 51.56 (C-13), 56.48 (C-14), 77.43 (C-15), 123.89 (C-16), 154.22 (C-17), 22.46 (C-18), 19.62 (C-19), 27.78 (C-20), 20.22 (C-21), 48.54 (C-22), 207.57 (C-23), 48.29 (C-24), 35.27 (C-25), 176.17 (C-26), 16.99 (C-27), 28.83 (C-28), 16.65 (C-29), 23.46 (C-30), 52.10 (C-O-Me).

Compound **2** was obtained as a yellow oily solid, yielded a positive reaction to 10% H~2~SO~4~--EtOH reagent. The structure was the same as that of compound **1**, except for the substituent of C-26, with a carboxy group on it. ^1^H-NMR (C~5~D~5~N, 500 MHz) δ: 3.11 (1H, m, H-3), 4.47 (1H, dd, *J* = 5.2, 8.9 Hz, H-7), 5.38 (1H, s, H-15), 5.21 (1H, s, H-16); ^13^C-NMR (CD~3~OD, 125 MHz) δ: 78.82 (C-3), 70.10 (C-7), 161.91 (C-8), 142.65 (C-9), 201.68 (C-11), 77.96 (C-15), 125.61 (C-16), 155.77 (C-17), 209.82 (C-23), 179.6 (C-26).

Compound **3** was obtained as a yellow oily solid, yielded a positive reaction to 10% H~2~SO~4~--EtOH reagent. The structure was the same as that of compound **1**, except for its more than a hydroxyl of C-28 and opposite stereoconfiguration of chiral C-15. ^1^H-NMR (C~5~D~5~N, 500 MHz) δ: 4.29 (1H, m, H-3), 5.09 (1H, m, H-7), 5.96 (1H, brs, H-15), 5.59 (1H, brs, H-16), 4.22 (1H, d, *J* = 10.5 Hz, H-28), 3.76 (1H, d, *J* = 10.5 Hz, H-28); ^13^C-NMR (C~5~D~5~N, 125 MHz) δ: 71.9 (C-3), 69.3 (C-7), 161.7 (C-8), 141.6 (C-9), 200.0 (C-11), 77.3 (C-15), 125.8 (C-16), 154.6 (C-17), 210.3 (C-23), 183.2 (C-26), 66.6 (C-28).

Compound **4** was obtained as a white amorphous power, yielded a positive reaction to 10% H~2~SO~4~--EtOH reagent. The structure was possessed two oxygenic five-membered rings system in the side chain of lanostane skeleton. ^1^H-NMR (C~5~D~5~N, 500 MHz) δ: 3.20 (dd, *J* = 6.0, 11.6 Hz, H-3α), 4.37 (1H, d, *J* = 6.6 Hz, H-7α), 5.30 (1H, m, H-15β), 2.28 (1H, m, H-20), 1.85 (1H, d, *J* = 13.5 Hz, H-22α), 2.83 (dd, *J* = 8.0, 14.7 Hz, H-22β), 2.62 (dd, *J* = 6.4, 13.8 Hz, H-24α), 2.08 (1H, m, H-24β), 2.87 (1H, m, H-25), 1.21 (3H, d, *J* = 7.1 Hz, H-27); ^13^C-NMR (C~5~D~5~N, 125 MHz) δ: 77.43 (C-3), 69.09 (C-7), 161.12 (C-8), 141.77 (C-9), 200.24 (C-11), 72.83 (C-15), 45.54 (C-16), 95.21 (C-17), 44.05 (C-20), 17.97 (C-21), 44.50 (C-22), 113.29 (C-23), 44.57 (C-24), 35.66 (C-25), 178.64 (C-26), 15.01 (C-27).

Compound **5** was obtained as a white solid, yielded a positive reaction to 10% H~2~SO~4~--EtOH reagent. The structure was the same as that of compound **1**, except for its the degradation of the carboxyl group and the attachment of a hydroxyl group to C-25 and opposite stereoconfiguration of chiral C-15, with its more than two H atoms of C-16 and C-17. ^1^H-NMR (DMSO-*d*~6~, 500 MHz) δ: 3.20 (1H, dd, *J* = 5.2, 11.0 Hz, H-3), 4.42 (1H, dd, *J* = 7.3, 9.8 Hz, H-7), 4.68 (1H, t, *J* = 15.8 Hz, H-15), 4.12 (1H, m, H-25), 1.81 (2H, m, H-16); ^13^C-NMR (DMSO-*d*~6~, 125 MHz) δ: 78.07 (C-3), 67.39 (C-7), 160.72 (C-8), 140.89 (C-9), 199.45 (C-11), 70.5 (C-15), 36.57 (C-16), 47.89 (C-17), 213.84 (C-23), 76.39 (C-25).

Compound **6** was obtained as a white amorphous powder, yielded a positive reaction to 10% H~2~SO~4~--EtOH reagent. The structure was most likely a lanostane triterpenoid with the presence of a trisubstituted C=C bond at C-24. ^1^H-NMR (C~5~D~5~N, 500 MHz) δ: 3.46 (1H, dd, *J* = 7.8,12.7 Hz, H-3), 3.48 (1H, d, *J* = 9.5 Hz, H-7), 5.23 (1H, t, *J* = 6.6 Hz, H-24), 2.97 (1H, dd, *J* = 8.6, 14.9 Hz, H-1), 1.67 (2H, m, H-2), 1.73 (2H, m, H-6), 1.87 (1H, m, H-15), 1.73 (1H, m, H-15), 2.65 (1H, d, *J* = 15.7 Hz, H-12), 2.56 (1H, d, *J* = 15.7 Hz, H-12), 2.00 (2H, m, H-16), 1.88 (1H, m, H-23), 1.62 (3H, s, H-26), 1.51 (3H, s, H-27); ^13^C-NMR (C~5~D~5~N, 125 MHz) δ: 77.48 (C-3), 69.35 (C-7), 160.42 (C-8), 141.78 (C-9), 199.93 (C-11), 29.98 (C-15), 27.84 (C-16), 50.10 (C-17), 23.50 (C-23), 123.88 (C-24), 135.10 (C-25), 23.50 (C-26), 17.42 (C-27).

Compound **7** was obtained as a white amorphous powder, yielded a positive reaction to 10% H~2~SO~4~--EtOH reagent. ^1^H-NMR (C~5~D~5~N, 500 MHz) δ: 8.32 (1H, d, *J* = 7.8 Hz, 2-NH), 6.02 (1H, m, 3-OH), 3.83 (1H, m, H-1), 4.86 (1H, d, *J* = 7.8 Hz, H-3), 4.50 (1H, t, H-4), 5.28 (1H, m, H-5), 3.97 (1H, m, H-8), 1.59 (3H, s, 9-CH3), 6.00 (1H, m, 2′-OH), 0.84 (6H, m, H-18, 16′, terminal methyls); ^13^C-NMR (C~5~D~5~N, 125 MHz) δ: 14.23 (C-1), 30.27, 29.99, 29.99, 29.97, 29.97, 29.89, 29.89 (C-2-8), 32.08 (C-9), 124.06 (C-10), 131.8 (C-11), 35.56 (C-12), 33.00 (C-13), 132.33 (C-14), 135.58 (C-15), 72.2 (C-16), 54.45 (C-17), 70.04 (C-18), 32.08 (C-19), 14.23 (C-1′), 16.01 (C-2′), 29.86, 29.86, 29.83, 29.78, 29.58, 29.30, 28.26, 28.11, 25.82, 22.89, 22.77 (C-3′-13′), 39.93 (C-14′), 72.39 (C-15′), 175.66 (C-16′), 105.54 (C-1′′), 75.00 (C-2′′), 78.31 (C-3′′), 71.36 (C-4′′), 78.44 (C-5′′), 62.50 (C-6′′).

Compound **8** was obtained as a white solid, which when sprayed with 10% H~2~SO~4~ ethanol solution followed by heating showed a blue purple color. ^1^H-NMR (DMSO-*d*~6~, 500 MHz) δ: 5.07 (1H, m, H-7), 5.23 (1H, m, H-22), 5.16 (1H, dd, *J* = 15.3, 8.1 Hz, H-23), 4.21 (1H, d, *J* = 5.6 Hz, OH-3), 3.75 (1H, m, H-3), 3.58 (1H, s, OH-5), 4.48 (1H, d, *J* = 5.5 Hz, OH-6), 3.36 (1H, brs, H-6), 2.02--1.82 (6H, m, H-2, 9, 12, 20, 24), 1.82--1.76 (1H, m, H-14), 1.68--1.62 (2H, m, H-16 ), 1.60--1.20 (11H, m, H-1, 2, 4, 11, 15, 17, 25), 0.53 (3H, s, H-18), 0.88 (3H, s, H-19), 0.98 (3H, d, *J* = 6.6 Hz, H-21), 0.79 (3H, d, *J* = 7.2 Hz, H-26), 0.87 (3H, d, *J* = 6.6 Hz, H-27 ), 0.80 (3H, d, *J* = 7.2 Hz, H-28); ^13^C-NMR (DMSO-*d*~6~, 125 MHz) δ: 21.29 (C-1), 40.17 (C-2), 65.92 (C-3), 31.15 (C-4), 74.43 (C-5), 72.09 (C-6), 119.41 (C-7), 139.62 (C-8), 42.23 (C-9), 36.61 (C-10), 32.42 (C-11, C-25), 38.93 (C-12), 42.95 (C-13), 54.13 (C-14), 22.55 (C-15), 27.67 (C-16), 55.28 (C-17), 12.02 (C-18), 17.65 (C-19), 40.00 (C-20), 20.94 (C-21), 135.34 (C-22), 131.34 (C-23), 41.96 (C-24), 19.70 (C-26), 19.42 (C-27), 17.24 (C-28).

2.2. Pharmacophoric Profiling of GTs {#sec2dot2-molecules-21-00678}
------------------------------------

Reverse pharmacophoric profiling of six isolated GTs and two positive GTs (GT-A and GT-D) was implemented to explore the pharmacological activity of GTs. In total, the reverse profiling results of eight GTs contained 30 human targets, and targets from the other creatures were eliminated because of less correlation with cancer. Top 20 interaction information of GTs and targets were showed in [Table 1](#molecules-21-00678-t001){ref-type="table"}, based on the hit number of SBP models and fit values. Compound **1**, **2**, **3**, and **5** and two positive GTs could match with CDK2 pharmacophore model (PDB: 1KE5) with fit value more than 0.5, which indicated they might have better biological action to CDK2. The superior mapping result of compound **3** and the best model was showed in [Figure 1](#molecules-21-00678-f001){ref-type="fig"}. In general, the structural framework of the eight GTs is oxygenated lanostane, wherein the chemical structure of compound **1**, **2**, **3** and **5** are more similar to that of GA-A and GA-D, because the branch chain of substituent of C-17 is a straight chain, including carboxyl, hydroxyl, or methyl ester, which might be the common structural basis of CDK2 activities, while, the branch chain of compound **4** had two oxygenated quaternary carbons (C-23 and C-17) instead of the carbonyl (C-23) and methyl (C-17) in compound **3**, and the branch chain of compound **6** had also no carbonyl or hydroxyl (C-23), which may be the cause of poor biological action to CDK2.

In order to observe the biological effect of GTs visually, ingredient-target network of GTs was constructed in [Figure 2](#molecules-21-00678-f002){ref-type="fig"}. According to the classes of corresponding diseases and the number of interactive compounds for each target, 19 high frequency targets were obtained, which could interact with more than one compound. As shown in the top of network, eight targets interacted with GA-A and GA-D could also be hit by the other six GTs, including CYP2C9, CDK2, PPAR γ, GCN5, MEK1, PTP1B, COX1, and COX2. It indicated that GTs might have common pharmacological activities related to cancer, cardiovascular diseases and metabolic syndrome. The 11 specific high-frequency targets of six isolated GTs were shown in the bottom of network, which included the cancer-related targets (CDK5, c-Met, Pim-1, Chk1, and Syk), metabolism-related targets (FXR, CYP3A4, 11beta-HSD1, FGFR1, PDE5A) and immune-related targets of Lck. These 11 specific targets of six isolated GTs might suggest specific pharmacological activities of GTs based on this extraction process. Other non-high-frequency targets might indicate miscellaneous pharmacological activities of GTs, which needed to analyze each ingredient-target interaction of a single GT. A brief description of high frequency targets was given in [Table 2](#molecules-21-00678-t002){ref-type="table"}.

2.3. Protein Interaction Network Analysis of GTs {#sec2dot3-molecules-21-00678}
------------------------------------------------

In this study, 19 high frequency targets were used to construct PIN ([Figure 3](#molecules-21-00678-f003){ref-type="fig"}) for further predicting the anti-cancer activity of GTs. The generated network contained 185 nodes (proteins) and 733 edges (relations). In order to cluster the pharmacological activity of GTs, 12 modules ([Figure 4](#molecules-21-00678-f004){ref-type="fig"}) were identified from PIN by MCODE algorithm. Functional enrichment analysis by BinGO method was shown in [Table 3](#molecules-21-00678-t003){ref-type="table"} to annotate potential biological function of the proteins in each module. The results showed that GTs played an essential role in pharmacodynamics with the biological processes, such as regulation of the cell division cycle, lipid metabolic process, protein acetylation, apoptotic signaling pathway, and so on. Half of the modules were related to cancer, including module 1, 3, 6, 7, and 11.

Histone acetylation (HAT) of module 1 was closely related to cancer, including KAT2A, TAF10, TAF9, TADA2A, TADA3, and so on. KAT2A is the gene name of GCN5, which is a typical transcriptional cofactor and requirement for HAT \[[@B34-molecules-21-00678]\]. GCN5 could form multiple complexes by TAFs, including TAF9 \[[@B35-molecules-21-00678],[@B36-molecules-21-00678]\], TADA2A, TADA3 \[[@B37-molecules-21-00678]\], which is quite essential to cancer and HAT. TAFs are important to regulate the cellular differentiation and the speed of cancer cell migration \[[@B37-molecules-21-00678]\]. TAFs are also the important part of transcription factor complex IID (TFIID), which could regulate and control cellular totipotency and differentiation in cancerous and normal cells. Therefore, GTs might regulate HAT by acting GCN5, which was beneficial to inhibit tumor proliferation and metastasis.

Module 3 showed anti-cancer activity including CCNE1, CCNB1, RBL1, RB1 and CDK2. Cyclin-dependent kinase-2 (CDK2) is an important member in protein kinase family, which could regulate division cycle in eukaryotic cell \[[@B38-molecules-21-00678]\]. Previous study had demonstrated that overexpressing CDK2 would lead to abnormal regulation in cell cycle, which was the important feature for overexpression of cancer cells. CDK2 could also combine with cyclin (gene name: CCN) and phosphorylate downstream targets RB1 and RBL1 \[[@B39-molecules-21-00678],[@B40-molecules-21-00678]\]. Therefore, CDK2 inhibitors are essential for anti-cancer treatment. Based on the pharmacophoric profiling of GTs, GTs are possible to inhibit CDK2 activity for downregulating DNA replication and mitotic cell cycle.

Module 6 and module 7 indicated that GTs might play an important role in anti-tumor effect by regulating receptor tyrosine kinase signaling pathway, especially fibroblast growth factor receptor (FGFR) signaling pathway. Module 11 showed that GTs might inhibit the negative regulation of apoptosis by activating the serine/threonine protein kinase (Pim1), which could promote the apoptosis of tumor cells.

3. Materials and Methods {#sec3-molecules-21-00678}
========================

3.1. Plant Material {#sec3dot1-molecules-21-00678}
-------------------

The fruiting bodies of *G. lucidum* were collected from Hainan in February 2013. The samples were authenticated by Professor Chun-Sheng Liu (School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China). A voucher specimen (No.130201) has been deposited at the 513 lab of School of Chinese Pharmacy, Beijing University of Chinese medicine.

3.2. Extraction {#sec3dot2-molecules-21-00678}
---------------

The dried fruiting bodies of *G. lucidum* (30 kg) were milled and soaked into 240 L 70% ethanol in the ratio of 1:8 (*w*/*v*). The mixtures were left for 12 h at room temperature, and then refluxed for three times, each time for two hours. The extract was filtered through a Whatman number 3 filter paper and concentrated with the rotary evaporator (Shanghai Yarong Biochemical Instrument Company, Shanghai, China) at 55 °C to obtain the crude 70% ethanol extract of *G. lucidum*. The crude extract was dissolved in water (12 L), and extracted with ethyl acetate (12 L) and n-butyl alcohol (12 L) for three times, respectively. The extract was filtered and concentrated, yielded an ethyl acetate fraction (463 g, dry weight) and an n-butyl alcohol fraction (160 g, dry weight).

3.3. Isolation {#sec3dot3-molecules-21-00678}
--------------

The ethyl acetate fraction was subjected to silica gel (500 g, 200--300 μm, 150 × 10 cm, Qingdao Haiyang Chemical Co., Ltd., Qingdao, China) dry column chromatography using CHCl~3~:EtOAc (4:1) as the eluent, yielded 40 fractions. The 40 fractions were then combined to five groups (F1 to F5) according to the thin layer chromatography (TLC) (20 cm × 20 cm, Qingdao Haiyang Chemical Co., Ltd.).

The F1 fraction (20.0 g) was fractionated into four groups (F~1~1 to F~1~4) with petroleum ether: EtOAc (100:0, 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, 0:100) according to the TLC. F~1~1 and F~1~2 were applied to precipitation crystallization, filtering, recrystallization to obtain compounds **23** and **24**. F~1~3 was subjected to CHCl~3~: EtOAc (2:1) as the eluent, then applied to preparation TLC (Qingdao Haiyang Chemical Co., Ltd.) with petroleum ether: chloroform: methanol (5:5:1) as mobile phase to obtain compound **9**. F~1~3 was subjected to a silica gel column chromatography using CHCl~3~:MeOH (5:1) as mobile phase to obtain compound **10**.

The F2 fraction (78 g) was fractioned into three groups with CHCl~3~: MeOH (80:1, 40:1, 20:1, 9:1, 8:2 , 7:3, 1:1, 3:7 and 0:1) according to the TLC. F~2~1 was rechromatographed over silica gel column using petroleum ether: EtOAc (1:1) as mobile phase to obtain compound **6**. F~2~2 was also subjected to a silica gel column using CH~2~Cl~2~: MeOH (1:1) as the eluent, and further applied to Sephadex LH-20 column (Merck, Darmstadt, Germany), ODS-A (20--45 μm; Merck, Darmstadt, Germany) and MCI-gel CHP-20-P (75--150 μm; Mitsubishi Chemical Co., Tokyo, Japan) with a step gradient of MeOH/H~2~O to yield compounds **11**, **12**, **13**.

Fraction F3 (55.0 g) was subjected to a silica gel column (75 g, 200--300 μm, 33 cm × 8 cm, Qingdao Haiyang Chemical Co., Ltd.) and eluted with a step gradient of CH~2~Cl~2~/MeOH (80:1, 40: 1, 20:1, 10:1, 9:1, 7:1, 4:1, 1:1, 0:1) to yield seven groups (F~3~1--F~3~7). F~3~1was submitted to column chromatography using CH~2~Cl~2~:MeOH (3:1) as mobile phase to yield compound **4**. F~3~3 and F~3~4 were further subjected with Sephadex LH-20, ODS-A and MCI-gel CHP-20-P, and eluted with a step gradient of MeOH:H~2~O to obtain compounds **1**, **2**, **5**, **8**. F~3~3, F~3~4, and F~3~5 were subjected to a silica gel chromatography eluted with a CH~2~Cl~2~:MeOH:H~2~O (30:1:0--8:2:0.2), and further reapplied to Sephadex LH-20, ODS-A, and MCI-gel CHP-20-P column, and using MeOH as eluting solvents to yield compounds **14**, **16**, **17**, **18**, **19**, **15**. The F~3~4 fraction (10 g) was subjected to Sephadex LH-20 and MCI-gel CHP-20-P open column using MeOH as eluting solvents to yield compound **3**.

A 160 g sample of n-butyl alcohol extract was fractionated into three groups according to the TLC with EtOAc: MeOH in the following ratios of 20:1, 10:1, 7:1, 5:1, 3:1, 1:1. Fraction 1 and 3 were applied to silica gel column using a step gradient of CH~2~Cl~2~/MeOH/H~2~O (40:1:0--7:3:0.5) as mobile phase, and further submitted to Sephadex LH-20, ODS-A, and MCI-gel CHP-20-P, and eluted with MeOH/H~2~O to yield compounds **7**, **20**, **21**, **22**. The structures of compounds **1**--**24** are shown in [Figure 5](#molecules-21-00678-f005){ref-type="fig"}.

3.4. Reverse Target Identification {#sec3dot4-molecules-21-00678}
----------------------------------

Ligand profile module was utilized to reversely identify targets for six isolated and two known positive GTs in Discovery Studio 4.0 (DS, Accelrys Inc., San Diego, CA, USA). Previous researches indicated GA-A and GA-D have the clear anti-cancer activity \[[@B18-molecules-21-00678],[@B41-molecules-21-00678]\]. Therefore, in this paper, GA-A and GA-D were selected to be the typical positive compounds for guiding the anti-cancer bioactive prediction of six isolated GTs. Eight compounds were first minimized in CHARMm force field with MMFF 94 partial charge. Diverse conformations of 8 GTs were constructed by the BEST method within 255 conformations, and the relative energy threshold was set to 20.0 kcal/mol.

Eight GTs were *in silico* profiled by structure-based pharmacophore (SBP) models database called pharmaDB in DS \[[@B42-molecules-21-00678],[@B43-molecules-21-00678],[@B44-molecules-21-00678]\]. In order to evaluate the predict activity of GTs, two indexes were chosen to judge the predicted results. The initial judgment criterion was the overlap degree of molecules and pharmacophore, which was represented by the fit value \[[@B45-molecules-21-00678]\]. Fit value greater than 0.5 indicated better-quality conformational coverage between compounds and SBP, which suggested potential biological activity of compounds for corresponding target. The second judgment criterion was the hit number of SBP models, which could to some extent reveal the biological activity of compounds and importance of the target. As SBP models were constructed by the crystal structure in the RCSB protein data bank (PDB), one target might have more than one crystal structure, and meanwhile one crystal structure could produce several SBP models. Therefore, a single target could have multiple SBP models, which represented various binding modes between ligands and receptors \[[@B46-molecules-21-00678]\]. According to the two indexes, the results of predicted targets and interaction were obtained with the fit value more than 0.5 and the rank of hit number of SBP models. Based on the result of reverse target identification, ingredient-target network of GTs was structured in Cytoscape 3.2.0 (Cytoscape Consortium, San Diego, CA, USA) \[[@B47-molecules-21-00678]\]. The high-frequency targets and pharmacological action of GTs were predicted and validated by the analysis of network nodes and edges.

3.5. Network Construction and Analysis {#sec3dot5-molecules-21-00678}
--------------------------------------

The PPI information of high-frequency targets was derived from the online database of String 9.1 \[[@B48-molecules-21-00678]\] which could provide experimental and predicted PPI information. Confidence scores could be provided from String, which represented the stable degree of interaction. In this paper, the PPIs of high-frequency targets, with a confidence score higher than 0.9, were collected to construct PIN by Cytoscape 3.2.0. Then, union calculation was implemented and duplicated edges of PPIs were removed by Advanced Network Merge \[[@B49-molecules-21-00678]\]. Finally, the largest connected sub-graph was obtained as the PIN of GTs.

A functional module is the structural unit of PIN, which can represent cellular functional organization and extract meaningful information from the complex PIN. In this paper, functional modules with more than four sides were identified by the MCODE methods \[[@B50-molecules-21-00678]\]. Based on the identified modules of GTs, GO enrichment analysis was used to predict possible biological processes of the identified modules using the BinGO method \[[@B51-molecules-21-00678]\]. Wherein, *p*-value was utilized to represent the probability that a group of genes was from the same gene ontology, and less *p*-value indicated more probability.

4. Conclusions {#sec4-molecules-21-00678}
==============

*G. lucidum* is one of the most commonly used TCM for thousands of years. The discovery of therapeutic basis and action mechanism of *G. lucidum* was essential to clinical use of drugs from *G. lucidum*. In this paper, an innovated research mode of extraction, isolation, pharmacological prediction, and PIN analysis was presented to discover the novel compounds and predict the anti-cancer activity of *G. lucidum*. Twenty-four compounds were isolated and identified from the 70% ethanol extract of the fruiting bodies of *G. lucidum*, including nineteen triterpenes, three steroids, one cerebroside, and one thymidine. Six GTs (Compounds **1**--**6**) were first reported from the species of *G. lucidum*. One cerebroside and one steroid were first isolated from the genus *Ganodema*. Then, pharmacophoric profiling of these six GTs was implemented to analyze their potential therapeutic targets. Nineteen high-frequency targets were obtained and mainly related to cancer and metabolic syndrome, especially CDK2 and PPAR γ. PIN and modules analysis of the 19 high frequency targets indicated that the cell division cycle regulating and protein acetylation might be the main anti-cancer mechanism of these six GTs. In this paper, molecular simulation and PIN analysis were directly utilized to research the potential activity of isolated compounds from the source of extraction of TCM. Actually, the results also need to be validated by wet experiments. However, compared to biochemistry and animals experiment, it might be a rapid, economical, and efficient method for discovering potential pharmacological activity of new isolated compounds.
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![CDK2 SBP model (PDB: 1KE5) and molecular mapping of the Compound **3**.](molecules-21-00678-g001){#molecules-21-00678-f001}

![Ingredient-target network of GTs.](molecules-21-00678-g002){#molecules-21-00678-f002}

![PIN of GTsbased on 19 frequency targets with 185 nodes (proteins) and 733 edges (relations).](molecules-21-00678-g003){#molecules-21-00678-f003}

![A set of 12 modules were identified from the PIN of GTs.](molecules-21-00678-g004){#molecules-21-00678-f004}

###### 

Structures of compounds **1**--**24**.

![](molecules-21-00678-g005a)

  Compound   R~1~   R~2~   R~3~
  ---------- ------ ------ -------
  **1**      H      β-OH   CH~3~
  **2**      H      β-OH   H
  **3**      -OH    α-OH   H

![](molecules-21-00678-g005b)

  Comp.    R~1~      R~2~
  -------- --------- ----------
  **5**    α-CH~3~   OH
  **16**   α-CH~3~   COOH
  **17**   β-CH~3~   COOCH~3~
  **19**   α-CH~3~   COOCH~3~
  **21**   β-CH~3~   COOH

![](molecules-21-00678-g005c)

  Comp.    R~1~   R~2~   R~3~   R~4~   R~5~      R~6~   R~7~
  -------- ------ ------ ------ ------ --------- ------ -------
  **6**    β-H    α-OH   =O     β-H    α-CH~3~   β-H    CH~3~
  **13**   α-H    =O     H      α-H    α-CH~3~   β-H    COOH
  **15**   α-H    β-OH   =O     α-H    β-CH~3~   β-OH   COOH
  **18**   β-H    β-OH   =O     β-H    α-CH~3~   β-H    COOH

![](molecules-21-00678-g005d)

  Comp.    R~1~   R~2~   R~3~   R~4~   R~5~   R~6~      R~7~
  -------- ------ ------ ------ ------ ------ --------- ----------------
  **10**   β-OH   α-H    β-OH   β-OH   =O     β-CH~3~   (CH~2~)~2~COOH
  **11**   =O     α-H    β-OH   β-H    α-OH   α-CH~3~   =O
  **12**   β-OH   α-H    =O     β-H    =O     α-CH~3~   =O
  **14**   β-OH   β-H    β-OH   β-H    α-OH   α-CH~3~   CH~2~OH

![](molecules-21-00678-g005e)

molecules-21-00678-t001_Table 1

###### 

Top 20 interaction information of GTs and targets.

  Compound   Target   Fitvalue   Hit \*   Compound   Target         Fitvalue   Hit \*
  ---------- -------- ---------- -------- ---------- -------------- ---------- --------
  Com3       CDK2     0.891      13       Com6       CYP3A4         0.792      5
  Com2       CDK2     0.817      12       Com5       CYP3A4         0.763      5
  Com5       CDK2     0.824      11       GA-A       CDK2           0.753      5
  Com1       CDK2     0.796      11       Com3       11beta-HSD 1   0.83       4
  Com2       PPAR γ   0.787      10       Com2       COX1           0.824      4
  Com3       PPAR γ   0.789      7        Com3       PTP 1B         0.724      4
  Com5       PPAR γ   0.833      6        Com2       c-Met          0.722      4
  Com2       CYP3A4   0.909      5        Com2       Lck            0.666      4
  Com1       CYP3A4   0.902      5        Com3       PPAR *γ*       0.635      4
  Com3       CYP3A4   0.883      5        GA-D       CDK2           0.707      3

\* Hit is the hit number of SBP models from one target.

molecules-21-00678-t002_Table 2

###### 

Predicted target information of GTs.

  ID   Target         Number of Compounds   Gene Name   Possibly Relevant Diseases
  ---- -------------- --------------------- ----------- -------------------------------------------------------
  1    CYP2C9         **8**                 CYP2C9      ADMET
  2    CDK2           **6**                 CDK2        cancer
  3    GCN5           **6**                 KAT2A       cancer
  4    PPAR γ         **5**                 PPARG       obesity
  5    COX1           **5**                 PTGS1       pain, cardiovascular diseases
  6    MEK1           **5**                 MAP2K1      cancer
  7    CYP3A4         **5**                 CYP A4      ADMET
  8    11beta-HSD 1   **5**                 HSD11B1     diabetes, obesity
  9    PDE5A          **5**                 PDE 5A      cardiovascular diseases
  10   PTP1B          **4**                 PTPN1       diabetes, obesity
  11   Syk            **4**                 Syk         cancer
  12   Lck            **4**                 Lck         autoimmune suppression
  13   c-Met          **4**                 MET         cancer
  14   Chk1           **4**                 Chk1        cancer
  15   Pim-1          **4**                 Pim-1       cancer
  16   CDK5           **3**                 CDK5        cognitive defects, cancer
  17   COX2           **2**                 Ptgs2       pain, inflammation
  18   FXR            **2**                 NR1H4       ADMET, bile acid-induced hepatotoxicity
  19   FGFR1          **2**                 FGFR1       diabetic retinopathy, cardiovascular diseases, cancer

molecules-21-00678-t003_Table 3

###### 

GO biological process terms of the modules display partially.

  Modules          *p*^−^Value                                   GO Terms
  ---------------- --------------------------------------------- ------------------------------------------------------------------
  Module 1         1.69 × 10^−21^                                histone acetylation
  Module 2         1.83 × 10^−13^                                cellular lipid metabolic process
  Module 3         1.89 × 10^−18^                                interphase of mitotic cell cycle
  Module 4         1.47 × 10^−22^                                activation of protein kinase A activity
  7.75 × 10^−20^   cellular response to glucagon stimulus        
  Module 5         1.88 × 10^−12^                                antigen receptor^−^mediated signaling pathway
  1.21 × 10^−11^   positive regulation of response to stimulus   
  Module 6         7.82 × 10^−14^                                transmembrane receptor protein tyrosine kinase signaling pathway
  Module 7         1.57 × 10^−17^                                fibroblast growth factor receptor signaling pathway
  Module 8         1.03 × 10^−13^                                transcription initiation from RNA polymerase II promoter
  Module 9         8.98 × 10^−17^                                prostaglandin biosynthetic process
  Module 10        1.11 × 10^−15^                                xenobiotic metabolic process
  Module 11        1.30 × 10^−07^                                positive regulation of Rac protein signal transduction
  4.46 × 10^−06^   negative regulation of apoptotic process      
  Module 12        1.02 × 10^−10^                                glucocorticoid biosynthetic process

[^1]: These authors contributed equally to this work.
